ANIMAB – Trademark Portfolio

Entity Type: 99

ANIMAB holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ANIMAB and NANOPROTEC. The owner is based in Gent.

Technology Park 94

Gent 9052 , BE

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ANIMAB
ANIMAB
Registered 2023
Trademark
Serial #97771239
Registered 2023

Trademark Classifications

ANIMAB's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

40
Treatment & Processing (2 filings)

Treatment of materials

Frequently Asked Questions

How many trademarks does ANIMAB have?

ANIMAB has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does ANIMAB file in?

ANIMAB files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ANIMAB's most well-known trademarks?

ANIMAB's registered trademark portfolio includes well-known marks such as ANIMAB and NANOPROTEC. These are among 3 currently registered trademarks in the portfolio.

What is ANIMAB's trademark registration success rate?

ANIMAB has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.